SEARCH

SEARCH BY CITATION

References

  • 1
    Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230238.
  • 2
    Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 13181330.
  • 3
    Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: The Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006; 55: 14631469.
  • 4
    Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999–2010. Diabetes Care 2012; 35: 14361445.
  • 5
    Barshes NR, Wyllie S, Goss JA. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: Implications for intrahepatic grafts. J Leukoc Biol 2005; 77: 587597.
  • 6
    Robertson RP. Intrahepatically transplanted islets-strangers in a strange land. J Clin Endocrinol Metab 2002; 87: 54165417.
  • 7
    Shapiro AM, Gallant HL, Hao EG, et al. The portal immunosuppressive storm: Relevance to islet transplantation? Ther Drug Monit 2005; 27: 3537.
  • 8
    Merani S, Toso C, Emamaullee J, Shapiro AM. Optimal implantation site for pancreatic islet transplantation. Br J Surg 2008; 95: 14491461.
  • 9
    van der Windt DJ, Echeverri GJ, Ijzermans JN, Cooper DK. The choice of anatomical site for islet transplantation. Cell Transplant 2008; 17: 10051014.
  • 10
    Jia X, Sharma A, Kumagai-Braesch M, et al. Exendin-4 increases the expression of hypoxia-inducible factor-1alpha in rat islets and preserves the endocrine-cell volume of both free and macroencapsulated islet grafts. Cell Transplant 2012; 21: 12691283.
  • 11
    Doggrell SA. Exenatide extended-release; clinical trials, patient preference, and economic considerations. Patient Prefer Adherence 2013; 7: 3545.
  • 12
    Goke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993; 268: 1965019655.
  • 13
    Sharma A, Sorenby A, Wernerson A, Efendic S, Kumagai-Braesch M, Tibell A. Exendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetes. Diabetologia 2006; 49: 12471253.
  • 14
    Toyoda K, Okitsu T, Yamane S, et al. GLP-1 receptor signaling protects pancreatic beta cells in intraportal islet transplant by inhibiting apoptosis. Biochem Biophys Res Commun 2008; 367: 793798.
  • 15
    Cechin SR, Perez-Alvarez I, Fenjves E, et al. Anti-inflammatory properties of exenatide in human pancreatic islets. Cell Transplant 2011; 21: 633648.
  • 16
    Duncanson S, Sambanis A. Dual factor delivery of CXCL12 and Exendin-4 for improved survival and function of encapsulated beta cells under hypoxic conditions. Biotechnol Bioeng 2013; 110: 22922300.
  • 17
    Mao GH, Chen GA, Bai HY, Song TR, Wang YX. The reversal of hyperglycaemia in diabetic mice using PLGA scaffolds seeded with islet-like cells derived from human embryonic stem cells. Biomaterials 2009; 30: 17061714.
  • 18
    Giannoukakis N, Mi Z, Rudert WA, Gambotto A, Trucco M, Robbins P. Prevention of beta cell dysfunction and apoptosis activation in human islets by adenoviral gene transfer of the insulin-like growth factor I. Gene Ther 2000; 7: 20152022.
  • 19
    Mabley JG, Belin V, John N, Green IC. Insulin-like growth factor I reverses interleukin-1beta inhibition of insulin secretion, induction of nitric oxide synthase and cytokine-mediated apoptosis in rat islets of Langerhans. FEBS Lett 1997; 417: 235238.
  • 20
    Rhodes CJ. IGF-I and GH post-receptor signaling mechanisms for pancreatic beta-cell replication. J Mol Endocrinol 2000; 24: 303311.
  • 21
    Agudo J, Ayuso E, Jimenez V, et al. IGF-I mediates regeneration of endocrine pancreas by increasing beta cell replication through cell cycle protein modulation in mice. Diabetologia 2008; 51: 18621872.
  • 22
    Rives CB, des Rieux A, Zelivyanskaya M, Stock SR, Lowe WL Jr, Shea LD. Layered PLG scaffolds for in vivo plasmid delivery. Biomaterials 2009; 30: 394401.
  • 23
    Berchane NS, Carson KH, Rice-Ficht AC, Andrews MJ. Effect of mean diameter and polydispersity of PLG microspheres on drug release: Experiment and theory. Int J Pharm 2007; 337: 118126.
  • 24
    Giteau A, Venier-Julienne MC, Aubert-Pouessel A, Benoit JP. How to achieve sustained and complete protein release from PLGA-based microparticles? Int J Pharm 2008; 350: 1426.
  • 25
    Jang JH, Shea LD. Controllable delivery of non-viral DNA from porous scaffolds. J Control Release 2003; 86: 157168.
  • 26
    Jaklenec A, Hinckfuss A, Bilgen B, Ciombor DM, Aaron R, Mathiowitz E. Sequential release of bioactive IGF-I and TGF-beta 1 from PLGA microsphere-based scaffolds. Biomaterials 2008; 29: 15181525.
  • 27
    Gibly RF, Zhang X, Lowe WL, Shea LD. Porous scaffolds support extrahepatic human islet transplantation, engraftment and function in mice. Cell Transplant 2012; 22: 811819.
  • 28
    Yang Y, De Laporte L, Rives CB, et al. Neurotrophin releasing single and multiple lumen nerve conduits. J Control Release 2005; 104: 433446.
  • 29
    Salvay DM, Rives CB, Zhang X, et al. Extracellular matrix protein-coated scaffolds promote the reversal of diabetes after extrahepatic islet transplantation. Transplantation 2008; 85: 14561464.
  • 30
    Blomeier H, Zhang X, Rives C, et al. Polymer scaffolds as synthetic microenvironments for extrahepatic islet transplantation. Transplantation 2006; 82: 452459.
  • 31
    Kheradmand T, Wang S, Gibly RF, et al. Permanent protection of PLG scaffold transplanted allogeneic islet grafts in diabetic mice treated with ECDI-fixed donor splenocyte infusions. Biomaterials 2011; 32: 45174524.
  • 32
    Suszynski TM, Wildey GM, Falde EJ, et al. The ATP/DNA ratio is a better indicator of islet cell viability than the ADP/ATP ratio. Transplant Proc 2008; 40: 346350.
  • 33
    Yap WT, Salvay DM, Silliman MA, et al. Collagen IV-modified scaffolds improve islet survival and function and reduce time to euglycemia. Tissue Eng Part A 2013; 19: 23612372.
  • 34
    Gibly RF, Zhang X, Graham ML, et al. Extrahepatic islet transplantation with microporous polymer scaffolds in syngeneic mouse and allogeneic porcine models. Biomaterials 2011; 32: 96779684.
  • 35
    Yook S, Jeong JH, Jung YS, et al. Molecularly engineered islet cell clusters for diabetes mellitus treatment. Cell Transplant 2012; 21: 17751789.
  • 36
    Jeong JH, Yook S, Jung Y, et al. Functional enhancement of beta cells in transplanted pancreatic islets by secretion signal peptide-linked exendin-4 gene transduction. J Control Release 2012; 159: 368375.
  • 37
    Butler PC, Meier JJ, Butler AE, Bhushan A. The replication of beta cells in normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab 2007; 3: 758768.
  • 38
    King A, Lock J, Xu G, Bonner-Weir S, Weir GC. Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment. Diabetologia 2005; 48: 20742079.
  • 39
    Olsson R, Carlsson PO. Better vascular engraftment and function in pancreatic islets transplanted without prior culture. Diabetologia 2005; 48: 469476.
  • 40
    Ghofaili KA, Fung M, Ao Z, et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 2007; 83: 2428.
  • 41
    Edwards KL, Stapleton M, Weis J, Irons BK. An update in incretin-based therapy: A focus on glucagon-like peptide-1 receptor agonists. Diabetes Technol Ther 2012; 14: 951967.
  • 42
    Liu B, Dong Q, Wang M, et al. Preparation, characterization, and pharmacodynamics of exenatide-loaded poly(d,l-lactic-co-glycolic acid) microspheres. Chem Pharm Bull (Tokyo) 2010; 58: 14741479.
  • 43
    DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(d,l-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011; 13: 11451154.
  • 44
    Lin CC, Anseth KS. Glucagon-like peptide-1 functionalized PEG hydrogels promote survival and function of encapsulated pancreatic beta-cells. Biomacromolecules 2009; 10: 24602467.
  • 45
    Kizilel S, Scavone A, Liu X, et al. Encapsulation of pancreatic islets within nano-thin functional polyethylene glycol coatings for enhanced insulin secretion. Tissue Eng Part A 2010; 16: 22172228.
  • 46
    Rush BT, Fraga DW, Kotb MY, et al. Preservation of human pancreatic islet in vivo function after 6-month culture in serum-free media. Transplantation 2004; 77: 11471154.
  • 47
    Leahy JL, Bonner-Weir S, Weir GC. Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 1992; 15: 442455.
  • 48
    Brissova M, Fowler MJ, Nicholson WE, et al. Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J Histochem Cytochem 2005; 53: 10871097.
  • 49
    Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci USA 2006; 103: 23342339.
  • 50
    Ulrich AB, Standop J, Schmied BM, Schneider MB, Lawson TA, Pour PM. Species differences in the distribution of drug-metabolizing enzymes in the pancreas. Toxicol Pathol 2002; 30: 247253.